IN THE CLAIMS

1. (Currently Amended) A pharmaceutical composition for cancer therapy ~~essentially~~ consisting essentially of:

a) at least one compound having glutaminase activity;

b) at least one antineoplastic agent selected from the group consisting of platinum complexes and anthracyclines; and

c) at least one of carrier substances, auxiliary substances, and pharmaceutical injection media.

2. (Currently Amended) The composition ~~as claimed in~~ of claim 1, ~~characterized in that~~

~~the~~ wherein said at least one compound having glutaminase activity is a glutaminase, glutaminase-asparaginase, glutaminase analogue, derivative or modification thereof and is either of natural origin or is produced synthetically.

3. (Currently Amended) The composition ~~as claimed in~~ of claim 2, ~~characterized in that the~~ wherein said at least one compound having glutaminase activity is ~~from Pseudomonas, preferably~~ Pseudomonas 7A glutaminase-asparaginase.

4. (Currently Amended) The composition ~~as claimed in~~ of claim 1, ~~characterized in that the~~ wherein said at least one compound having glutaminase activity is modified with polyethylene glycol.

5. (Currently Amended) The composition ~~as claimed in~~ of claim 1, ~~characterized in that the~~ wherein said anthracyclines comprise at least one of doxorubicin, daunomycin, actinomycin D and mitoxantrone.

6. (Currently Amended) The composition ~~as claimed in~~ of claim 1, ~~characterized in that the~~ wherein said platinum complexes comprise at least one of cis-platinum, oxaliplatinum and carboplatinum.

7. (Currently Amended) A process for producing the pharmaceutical composition as claimed in claim 1, ~~characterized in that the~~ wherein said active substances are processed into oral or parenteral forms of administration.

8. (Withdrawn) Use of in particular a compound having glutaminase activity and at least one antineoplastic agent selected from platinum complexes and anthracyclines to produce an agent for an antineoplastic therapy.

9. (Withdrawn) Method for treating cancer and other diseases which are associated with abnormal cell proliferation, characterized in that at least one compound having glutaminase activity and at least one antineoplastic agent selected from platinum complexes or anthracyclines are administered in a molar ratio between 1:10 to 1:1000 and 10:1 to 1000:1, where the doses to be administered daily are 0.005 – 100 mg/kg body weight per individual component.

10. (Currently Amended) The process ~~as claimed in~~ of claim 7, ~~characterized in that~~ ~~the~~ wherein said active substances are mixed together with common pharmaceutical carrier substances or auxiliary substances.